eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank

4/2019
vol. 44
 
Share:
Share:
more
 
 
Short communication

Etanercept in the treatment of Graves’ ophthalmopathy with primary hypothyroidism and rheumatoid arthritis

Olivera Boskovic
,
Sanja Medenica
,
Nemanja Radojevic
,
Milos Zarkovic

(Centr Eur J Immunol 2019; 44 (4): 463-465)
Online publish date: 2020/01/20
Article file
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Dear Editor,

In a relevant literature, Graves’ ophthalmopathy (GO) is defined as an autoimmune disease affecting ocular and orbital tissues [1], typically appearing in hyperthyroidism. Orbital fibroblasts have the central position in the pathogenesis of GO. Fibrocytes demonstrate an increased expression of the thyrotropin receptor (TSHR), comparable to the levels of thyroid epithelial cells, and ligation leads to a marked up-regulation of tumor necrosis factor (TNF)-α and interleukin (IL)-6 cytokine production [2]. Receptors for TNF-α, proinflammatory cytokine, have been demonstrated in thyroid follicular cells, indicating that TNF-α has been implicated in the cytotoxic mechanisms leading to the thyroid gland destruction in autoimmune thyroid disease [3]. Etanercept is a TNF inhibitor and, in clinical practice, is used for treatment of rheumatoid arthritis (RA).

This paper presents a female patient with both GO and RA, who was treated with, inter alia, etanercept for RA. This treatment led to an improvement of eye symptoms and the exophthalmos was reduced.

A 37-year-old woman complained of sleepiness, apathy, and fatigue. Her hormonal analyses were as follows: thyrotropin (TSH) 11 mU/l (reference range 0.47-5.01 mU/l), free tetraiodothyronine (fT4) 10.5 pmol/l (reference range 12-22 pmol/l), anti-thyroid peroxidase antibodies (TPOAbs) 364.5 IU/ml (reference range < 12 IU/ml), anti-thyroglobulin antibodies (TgAbs) 180.3 IU/ml (reference range < 12 IU/ml), and anti-thyrotropin receptor antibodies (TRAbs) 4.54 IU/ml (reference range < 1 IU/ml). Due to primary hypothyroidism, levothyroxine substitution was initiated. Ultrasonography of the thyroid gland showed its heterogeneous structure with a colloid nodule of the right lobe (15 mm in diameter). The patient was a smoker for the last 30 years. Her parents were middle aged when they suddenly passed, and her sister suffered from psoriatic arthritis.

At about the same time, she presented with pain in the small joints of hands, knees, and jaw, numbness in the forearms and lower legs, and had difficulties climbing stairs. She was diagnosed with seropositive RA, with the following laboratory results: RF 122.7 IU/ml (reference range < 53 IU/ml), Waaler-Rose and latex tests were positive, and anti-CCP was 813.6 (reference range < 18 IU/ml). In the following years, the patient was treated with chloroquine, hydroxychloroquine, sulfasalazine, and methotrexate, in sequence.

After three years, she began complaining of orbital ache, diplopia (Gorman score – intermittent diplopia). Physical examination revealed watery eyes, bilateral eyelid edema, and eyelid erythema as well as conjunctival eyelid redness and exophthalmos. Ophthalmological examination results, hormonal values, and imaging method results are presented in Table 1. At the time, she was euthyroid. She was advised in accordance with the Consensus statement of the European Group on Graves’ ophthalmopathy (EUGOGO) regarding the management of GO [4]. Over this time, the disease progressed to a moderate form. The administration of glucocorticoids was initiated and prednisone oral 0.5 mg/kg tapered down for 6 weeks. No significant improvement was achieved.

Table 1

Values of Graves’ ophthalmopathy related parameters

ParameterValues at the time of GO appearanceValues after etanercept treatmentReference range
TSH2.260.840.47-5.01 mU/l
TPOAbs273.545.0< 12 IU/ml
TgAbs11.232.5< 12 IU/ml
TRAbs4.541.54< 1 IU/ml
CAS41
Visus
right eye1.01.00.1-1.0
left eye1.01.0
IOP (mm Hg)
right eye182012-22 mm Hg
left eye2220
Exophthalmos*
right eye2321≤ 18 mm
left eye2321
CT
right superior rectus muscles8.38.0< 4 mm
left superior rectus muscles8.57.5

[i] GO – Graves’ ophthalmopathy, TSH – thyrotropin, TPOAbs – anti-thyroid peroxidase antibodies, TgAbs – anti-thyroglobulin antibodies, TRAbs – anti-thyrotropin receptor antibodies, CAS – clinical activity score, IOP – intraocular pressure, CT – computed tomography, * Hertel exophthalmometer by Oculus, Germany

Eighteen months after GO diagnosis, due to the insufficient therapeutic efficacy of her previous RA treatment, etanercept was administered in combination with methotrexate. Etanercept was given in a dose of 25 mg twice a week subcutaneously. After four months, an improvement of her eye symptoms and reduction in exophthalmos were noticed (Table 1). She experienced only mild eyelids edema.

The prevalence of GO in primary euthyroid and hypothyroid patients ranges between 1.6% and 8.6% [5]. Using etanercept in RA caused a clinical improvement of GO symptoms and signs. Visualization methods showed the reduction in the thickness of the extraocular muscles.

TRAbs in GO combine with the TSH receptors in retro-orbital tissues cause the lymphocytic infiltration and production of cytokines and glycosaminoglycans. TRAb is an antibody, which confirms the autoimmune form of GO. Fibrocytes in GO start to infiltrate orbital tissues during the inflammation process leading to overproduction of TNF-α. TNF-α has been suggested as a possible mediator of increased expression in the major histocompatibility complex (MHC) class I molecules on thyroid epithelial cells in GO.

Some novel immunosuppressors have already been employed in clinical studies and have shown interesting results, although the lack of randomized and controlled trials suggests caution in their use in clinical practice [6]. Studies in the body of literature have attempted to determine whether etanercept is effective in reducing the clinical signs of GO and whether it can be administered safely for a prolonged period of time without side effects. The effect of the TNF inhibitor, etanercept, on GO was discussed in a pilot study in 2005 [7], and the study showed a marked improvement in the evolution of the disease.

The presented case suggests that etanercept may suppress the symptoms and clinical signs in GO, but controlled trials are needed to further evaluate the effect of TNF-α inhibitors, particularly etanercept, and to compare its side effects with the current options for medical treatment. It is important to note that new discoveries about immunopathogenesis of GO will increase the application of TNF-α inhibitors in GO treatments, which is especially important for the patients at risk of progressive and severe diseases.

Acknowledgements

The case was presented as an oral presentation at the International Clinical Update in Endocrinology (ICUE), during the “Thyroid cases” session. It was held on February 1st and 2nd, 2014 in Hyderabad, India.

Authors wish to thank Sreten Kavaric, MD PhD, and Koviljka Kazic, MD, for providing professional assistance.

Notes

[2] Conflicts of interest The authors declare no conflict of interest.

References

1 

Eichhorn KHarrison ARBothun EDet al.. (2010): Ocular treatment for thyroid eye disease. Expert Rev Ophthalmol 5: 313-325.

2 

Douglas RSGupta S (2011): The pathophysiology of thyroid eye disease (TED): implications for immunotherapy. Curr Opin Ophthalmol 22: 385-390.

3 

Díez JJHernanz AMedina Set al.. (2002): Serum concentrations of tumour necrosis factor-alpha (TNF-αlpha) and soluble TNF-αlpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function. Clin Endocrinol (Oxf) 57: 515-521.

4 

Bartalena LBaldeschi LDickinson Aet al.. (2008): Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158: 273-285.

5 

Eckstein AKLösch CGlowacka Det al.. (2009): Euthyroid and Primarily Hypothyroid Patients Develop Milder and Significantly More Asymmetrical Graves Ophthalmopathy. Br J Ophthalmol 93: 1052-1056.

6 

Campi IVannucchi GSalvi M (2016): Therapy of endocrine disease: Endocrine dilemma: management of Graves’ orbitopathy. Eur J Endocrinol 175: R117-133.

7 

Paridaens Dvan den Bosch WAvan der Loos TLet al.. (2005): The effect of etanercept on Graves’ ophthalmopathy: a pilot study. Eye (Lond) 19: 1286-1289.

Copyright: © 2020 Polish Society of Experimental and Clinical Immunology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe